Muscle invasive bladder cancer (MIBC) is a molecularly diverse disease with varied clinical outcomes. Molecular studies typically employ bulk sequencing analysis, giving a transcriptomic snapshot of a section of the tumour. However, tumour tissues are not homogeneous, but are composed of distinct compartments such as the tumour and stroma. To investigate the molecular profiles of bladder cancer, whilst also maintaining the spatial complexity of the tumours, we employed whole transcriptome Digital Spatial Profiling (DSP). With this method we generated a dataset of transcriptomic profiles of tumour epithelium, stroma, and immune infiltrate. With these data we investigate the spatial relationship of molecular subtype signatures and ligand signalling events. We find that Basal/Squamous and Classical subtypes are mostly restricted to tumour regions, while the stroma-rich subtype signatures are abundant within the stroma itself. Additionally, we identify ligand signalling events occurring between tumour, stroma, and immune infiltrate regions, such as immune infiltrate derived GPNMB, which was highly correlated with VEGFA expression within the tumour. These findings give us new insights into the diversity of MIBC at a molecular level and provide a dataset with detailed spatial information that was not available before in bladder cancer research.
Hypoxia and a suppressive tumour microenvironment (TME) are both independent negative prognostic factors for muscle-invasive bladder cancer (MIBC) that contribute to treatment resistance. Hypoxia has been shown to induce an immune suppressive TME by recruiting myeloid cells that inhibit anti-tumour T cell responses. Recent transcriptomic analyses show hypoxia increases suppressive and anti-tumour immune signalling and infiltrates in bladder cancer. This study sought to investigate the relationship between hypoxia-inducible factor (HIF)-1 and -2, hypoxia, and immune signalling and infiltrates in MIBC. ChIP-seq was performed to identify HIF1α, HIF2α, and HIF1β binding in the genome of the MIBC cell line T24 cultured in 1% and 0.1% oxygen for 24 h. Microarray data from four MIBC cell lines (T24, J82, UMUC3, and HT1376) cultured under 1%, 0.2%, and 0.1% oxygen for 24 h were used. Differences in the immune contexture between high- and low-hypoxia tumours were investigated using in silico analyses of two bladder cancer cohorts (BCON and TCGA) filtered to only include MIBC cases. GO and GSEA were used with the R packages “limma” and “fgsea”. Immune deconvolution was performed using ImSig and TIMER algorithms. RStudio was used for all analyses. Under hypoxia, HIF1α and HIF2α bound to ~11.5–13.5% and ~4.5–7.5% of immune-related genes, respectively (1–0.1% O2). HIF1α and HIF2α both bound to genes associated with T cell activation and differentiation signalling pathways. HIF1α and HIF2α had distinct roles in immune-related signalling. HIF1 was associated with interferon production specifically, whilst HIF2 was associated with generic cytokine signalling as well as humoral and toll-like receptor immune responses. Neutrophil and myeloid cell signalling was enriched under hypoxia, alongside hallmark pathways associated with Tregs and macrophages. High-hypoxia MIBC tumours had increased expression of both suppressive and anti-tumour immune gene signatures and were associated with increased immune infiltrates. Overall, hypoxia is associated with increased inflammation for both suppressive and anti-tumour-related immune signalling and immune infiltrates, as seen in vitro and in situ using MIBC patient tumours.
Background: As hypoxia can drive an immunosuppressive tumour microenvironment and inhibit CD8+ T cells, we investigated if patients with low tumour CD8+ T cells benefitted from hypoxia-modifying therapy. Methods: BCON was a phase III trial that randomised patients with muscle-invasive bladder cancer (MIBC) to radiotherapy alone or with hypoxia-modifying carbogen plus nicotinamide (CON). Tissue microarrays of diagnostic biopsies from 116 BCON patients were stained using multiplex immunohistochemistry (IHC) with the markers CD8, CD4, FOXP3, CD68 and PD-L1, plus DAPI. Hypoxia was assessed using CA9 IHC (n = 111). Linked transcriptomic data (n = 80) identified molecular subtype. Relationships with overall survival (OS) were investigated using Cox proportional hazard models. Results: High (upper quartile) vs. low CD8 T cell counts associated with a better OS across the whole cohort at 16 years (n = 116; HR 0.47, 95% CI 0.28–0.78, p = 0.003) and also in the radiotherapy alone group (n = 61; HR 0.39, 95% CI 0.19–0.76, p = 0.005). Patients with low CD8+ T cells benefited from CON (n = 87; HR 0.63, 95% CI 0.4–1.0, p = 0.05), but those with high CD8 T cells did not (n = 27; p = 0.95). CA9 positive tumours had fewer CD8+ T cells (p = 0.03). Prognostic significance of low CD8+ T cells in the whole cohort remained after adjusting for clinicopathologic variables. Basal vs. luminal subtype had more CD8+ cells (p = 0.02) but was not prognostic (n = 80; p = 0.26). Exploratory analyses with other immune markers did not improve on findings obtained with CD8 counts. Conclusions: MIBC with low CD8+ T cell counts may benefit from hypoxia-modifying treatment.
Introduction: Hypoxia and an immunosuppressive tumor microenvironment (TME) are both independent negative prognostic factors that contribute to radiotherapy resistance in muscle-invasive bladder cancer (MIBC). Therefore, we sought to investigate the relationship between them and whether the immune TME can predict benefit from hypoxia-modifying therapy in the BCON trial that randomized MIBC patients to radiotherapy alone or with carbogen plus nicotinamide (CON). Methods: Tissue microarrays of diagnostic biopsies from 116 MIBC patients from the BCON trial were stained using Akoya Opal࣪ multiplex immunohistochemistry (IHC) reagents (CD8, CD4, FOXP3, CD68, PDL1, DAPI). Following multispectral scanning the slides were spectrally unmixed using Inform and marker proportion quantified using HALO software as the percentage of the total cell count per sample. Hypoxia was assessed as the presence of CA9 protein using IHC (n=111) and by using transcriptomic data (n=80) previously acquired to determine an hypoxia score (HS). Relationships with overall (OS) and local progression-free (LPFS) survival were assessed using Cox proportional hazard models and Kaplan-Meier curves in R. Molecular subtypes were determined using the consensusMIBC package in R. Results: Basal/squamous and stroma-rich vs other molecular subtypes had increased hypoxia scores and immune markers (CD8, CD4, CD68, PDL1). Tumors with CA9 present had significantly lower proportion of CD8 T cells (p=0.027), and CD4 T cells (p=0.01) but there were no significant differences for other immune markers or significant differences associated with HS. Only CD8 showed a relationship with survival and we found the relationship between log(HR) and CD8 to be non-linear, which led to placing patients within groups. Patients with a low vs high proportion of CD8 T cells had a significantly worse 2-year OS (n=116, p=0.003) and LPFS (n=116, p=0.02). CD8 proportion was also prognostic in patients receiving radiotherapy alone for OS (n=61; p=0.003) and LPFS (n=61; p=0.003). Patients with low CD8 T cells had improved OS when CON was given with radiotherapy (n=87; p=0.05), but those with high CD8 T cells derived no benefit (n=27; p=0.95). Prognostic significance of low CD8 T cells in the whole cohort remained after adjusting for clinicopathologic variables and hypoxia measured using CA9 (HR 0.32; 95% CI 0.18-0.57; p<0.001) while hypoxia had borderline significance (HR=0.62; 95% CI 0.37-1.02; p=0.059). Conclusions: Low proportion of CD8 T cells in the TME of MIBC patients has independent prognostic and predictive value. It can be used to identify patients likely to benefit from the addition of carbogen and nicotinamide to radiotherapy. Citation Format: Vicky Smith, Debayan Mukherjee, Anna Maria Tsakiroglou, Alexander Baker, Hitesh Mistry, Ananya Choudhury, Peter Hoskin, Tim Illidge, Catharine West. Low CD8 T cells predicts benefit from hypoxia-modifying therapy in bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6236.